Bicara Therapeutics (BCAX) Assets Average (2024 - 2026)

Bicara Therapeutics' Assets Average history runs 3 years deep, the most recent figure standing at $492.3 million for Q1 2026.

• In Q1 2026, Assets Average changed 0.35% year-over-year to $492.3 million; the TTM figure through Mar 2026 stood at $492.3 million (changed 0.35% YoY), while the FY2025 annual figure was $470.5 million, up 26.48% from the prior year.
• Assets Average for Q1 2026 stood at $492.3 million, up from $427.8 million in the prior quarter.
• The five-year high for Assets Average was $517.1 million in Q4 2024, with the low at $427.8 million in Q4 2025.
• The 3-year median for Assets Average is $479.1 million (2025), against an average of $472.7 million.
• The sharpest annual moves came in 2025 and 2026: Assets Average retreated 17.26% in 2025, then declined 0.35% in 2026.
• Bicara Therapeutics' Assets Average stood at $517.1 million in 2024, then fell by 17.26% to $427.8 million in 2025, then gained by 15.07% to $492.3 million in 2026.
• Business Quant data shows BCAX's Assets Average at $492.3 million in Q1 2026, $427.8 million in Q4 2025, and $439.1 million in Q3 2025.